+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nasopharyngeal Carcinoma Treatment Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • February 2024
  • Region: Global
  • The Business Research Company
  • ID: 5934001
The nasopharyngeal carcinoma treatment market size has grown strongly in recent years. It will grow from $1.13 billion in 2023 to $1.21 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The growth observed in the historic period for nasopharyngeal carcinoma treatment can be attributed to factors such as the high prevalence of the disease in endemic regions, advancements in radiation therapy, improved diagnostic methods, increased awareness, and the implementation of screening programs. Additionally, collaborative research initiatives have played a significant role in contributing to the overall progress in treating nasopharyngeal carcinoma during this period.

The nasopharyngeal carcinoma treatment market size is expected to see strong growth in the next few years. It will grow to $1.57 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The anticipated growth in the forecast period for nasopharyngeal carcinoma treatment can be attributed to the emergence of targeted therapies and personalized medicine approaches. Additionally, there is a global expansion of treatment access, significant successes in clinical trials, and a continued emphasis on early detection methods. The forecast period is expected to witness major trends, including the implementation of combination therapies, a focus on supportive care and quality of life, integration of artificial intelligence (AI) in treatment planning, expansion of clinical trials and research initiatives, and the adoption of enhanced imaging technologies for early detection.

The nasopharyngeal carcinoma treatment market is expected to witness growth propelled by the rise in tobacco consumption. Tobacco, derived from dried leaves of the tobacco plant, is commonly used for smoking or chewing and is a key component in various tobacco products. Increased tobacco use elevates the risk of developing nasopharyngeal carcinoma, necessitating effective treatment options such as surgery, radiation therapy, chemotherapy, and targeted therapies. Notably, Statistics Canada reported a 2.2% surge in cigarette production in Canada in July 2023 compared to June, coupled with a 2.6% increase in cigarette sales, reaching 1.4 billion units in June. Hence, the escalating tobacco consumption drives the expansion of the nasopharyngeal carcinoma treatment market.

The nasopharyngeal carcinoma treatment market is projected to grow due to an upsurge in Epstein-Barr virus (EBV) infections. EBV, a highly contagious infection belonging to the herpesvirus family, is closely linked to Nasopharyngeal Carcinoma (NPC). The virus spreads primarily through bodily fluids, notably saliva, and is strongly associated with NPC development. The National Library of Medicine reported a staggering 95% global adult population exposure to EBV in August 2023. Moreover, in the United States, EBV prevalence among children and adolescents varies, with infection rates around 54% in certain age groups and peaking at approximately 82.9% among adolescents aged 18 to 19. Consequently, the escalating incidence of EBV infections drives growth in the nasopharyngeal carcinoma treatment market.

The high cost of drug treatments poses a challenge and could restrain the growth of the nasopharyngeal carcinoma treatment market. Factors contributing to elevated costs include the intricate nature of surgeries, specialized equipment usage, and the expertise required for these procedures. This cost barrier may limit access to treatment for certain patients. For instance, according to the American Society of Clinical Oncology, the incremental drug costs for nasopharyngeal carcinoma treatments ranged from $133.46 to $626.14 in November 2021. Hence, the substantial cost of drug treatments acts as a hindrance to the market's expansion.

Major companies in the nasopharyngeal carcinoma treatment market are prioritizing the development of cutting-edge technologies, such as in vitro patient-derived 3D organoid models, to gain a competitive advantage. These in vitro hypoxic 3D organoid models are engineered structures mirroring low oxygen conditions within tissues, providing a platform for studying cellular behavior, diseases, and therapies in realistic settings. For instance, in April 2021, the Institute of Bioengineering and Nanotechnology (IBN) collaborated with the Singapore Institute of Advanced Medicine Holdings Pte Ltd (SIAMH) to pioneer in vitro patient-derived 3D organoid models specifically for nasopharyngeal cancer research. These advanced models facilitate the analysis, prediction, and determination of optimal radiobiological parameters for precise radiation dosing in nasopharyngeal cancer (NPC). The approach targets hypoxic and radioresistant tumor areas, potentially reducing recurrences. The research suggests a 1.4-fold radiation dose escalation to these regions, demonstrating enhanced treatment outcomes. Employing hypo-fractionated radiotherapy with higher doses may minimize side effects and recurrence rates, thereby improving patients' quality of life.

In January 2021, Novartis AG, a Switzerland-based pharmaceutical giant, secured the in-licensing rights for Tislelizumab from BeiGene Ltd. for an undisclosed sum. This strategic acquisition grants Novartis AG access to 'Tislelizumab,' an anti-PD-1 monoclonal antibody designed to impede anti-tumor activity in patients afflicted with nasopharyngeal carcinoma, esophageal squamous cell carcinoma, non-small cell lung cancer, and other malignancies. Novartis AG aims to leverage this acquisition to expedite growth in the inhibitor field across major markets. BeiGene Ltd., a biotechnology firm based in China, is committed to developing treatments for various cancers, including nasopharyngeal carcinoma (NPC).

Major companies operating in the nasopharyngeal carcinoma treatment market report are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., C.H. Boehringer Sohn AG & Co. KG., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd., Incyte Corporation, Ipsen S.A., Dr. Reddys Laboratories Ltd., Hikma Pharmaceuticals plc, Exelixis Inc., BeiGene Ltd, Taiho Pharmaceutical Co. Ltd., Simcere Pharmaceutical Group, Daiichi Sankyo Company Limited, BioDiem Ltd, Coherus BioSciences Inc., Shanghai Junshi Bioscience Co Ltd, Genentech Inc., Helsinn Group, Cyclacel Pharmaceuticals Inc., Advenchen Laboratories LLC.

North America was the largest region in the nasopharyngeal carcinoma treatment market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasopharyngeal carcinoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the nasopharyngeal carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nasopharyngeal carcinoma treatment market consists of revenues earned by entities by providing proton therapy, brachytherapy, external-beam radiation therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nasopharyngeal carcinoma treatment market also includes sales of loqtorzi, cetuximab, gemcitabine, and cisplatin used in nasopharyngeal carcinoma treatment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The main types of nasopharyngeal carcinoma include non-keratinizing undifferentiated carcinoma, non-keratinizing differentiated carcinoma, and keratinizing squamous cell carcinoma. Non-keratinizing undifferentiated carcinoma is characterized by the absence of keratin, a protein typically found in the outer layers of the skin. Treatment for this type of carcinoma typically involves a combination of radiation therapy and chemotherapy. Chemotherapy drugs such as ellence, taxotere, bleomycin, and methotrexate are employed in various treatment modalities, including chemotherapy, immunotherapy, radiation therapy, and others. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacy channels.

The nasopharyngeal carcinoma treatment market research report is one of a series of new reports that provides nasopharyngeal carcinoma treatment market statistics, including nasopharyngeal carcinoma treatment industry global market size, regional shares, competitors with a nasopharyngeal carcinoma treatment market share, detailed nasopharyngeal carcinoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the nasopharyngeal carcinoma treatment industry. This nasopharyngeal carcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Nasopharyngeal Carcinoma Treatment Market Characteristics3. Nasopharyngeal Carcinoma Treatment Market Trends and Strategies
4. Nasopharyngeal Carcinoma Treatment Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Nasopharyngeal Carcinoma Treatment Market Size and Growth
5.1. Global Nasopharyngeal Carcinoma Treatment Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Nasopharyngeal Carcinoma Treatment Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global Nasopharyngeal Carcinoma Treatment Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. Nasopharyngeal Carcinoma Treatment Market Segmentation
6.1. Global Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Non-Keratinizing Undifferentiated Carcinoma
  • Non-Keratinizing Differentiated Carcinoma
  • Keratinizing Squamous Cell Carcinoma
6.2. Global Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Ellence
  • Taxotere
  • Bleomycin
  • Methotrexate
6.3. Global Nasopharyngeal Carcinoma Treatment Market, Segmentation by Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Other Therapies
6.4. Global Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
7. Nasopharyngeal Carcinoma Treatment Market Regional and Country Analysis
7.1. Global Nasopharyngeal Carcinoma Treatment Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Nasopharyngeal Carcinoma Treatment Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Nasopharyngeal Carcinoma Treatment Market
8.1. Asia-Pacific Nasopharyngeal Carcinoma Treatment Market Overview
Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Nasopharyngeal Carcinoma Treatment Market
9.1. China Nasopharyngeal Carcinoma Treatment Market Overview
9.2. China Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Nasopharyngeal Carcinoma Treatment Market
10.1. India Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Nasopharyngeal Carcinoma Treatment Market
11.1. Japan Nasopharyngeal Carcinoma Treatment Market Overview
11.2. Japan Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Nasopharyngeal Carcinoma Treatment Market
12.1. Australia Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Nasopharyngeal Carcinoma Treatment Market
13.1. Indonesia Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Nasopharyngeal Carcinoma Treatment Market
14.1. South Korea Nasopharyngeal Carcinoma Treatment Market Overview
14.2. South Korea Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Nasopharyngeal Carcinoma Treatment Market
15.1. Western Europe Nasopharyngeal Carcinoma Treatment Market Overview
15.2. Western Europe Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Nasopharyngeal Carcinoma Treatment Market
16.1. UK Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Nasopharyngeal Carcinoma Treatment Market
17.1. Germany Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Nasopharyngeal Carcinoma Treatment Market
18.5. France Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.6. France Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.7. France Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Nasopharyngeal Carcinoma Treatment Market
19.9. Italy Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.10. Italy Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.11. Italy Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Nasopharyngeal Carcinoma Treatment Market
20.13. Spain Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.14. Spain Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.15. Spain Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Nasopharyngeal Carcinoma Treatment Market
21.1. Eastern Europe Nasopharyngeal Carcinoma Treatment Market Overview
21.2. Eastern Europe Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Nasopharyngeal Carcinoma Treatment Market
22.1. Russia Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Nasopharyngeal Carcinoma Treatment Market
23.1. North America Nasopharyngeal Carcinoma Treatment Market Overview
23.2. North America Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Nasopharyngeal Carcinoma Treatment Market
24.1. USA Nasopharyngeal Carcinoma Treatment Market Overview
24.2. USA Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Nasopharyngeal Carcinoma Treatment Market
25.1. Canada Nasopharyngeal Carcinoma Treatment Market Overview
25.2. Canada Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Nasopharyngeal Carcinoma Treatment Market
26.1. South America Nasopharyngeal Carcinoma Treatment Market Overview
26.2. South America Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Nasopharyngeal Carcinoma Treatment Market
27.1. Brazil Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Nasopharyngeal Carcinoma Treatment Market
28.1. Middle East Nasopharyngeal Carcinoma Treatment Market Overview
28.2. Middle East Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Nasopharyngeal Carcinoma Treatment Market
29.1. Africa Nasopharyngeal Carcinoma Treatment Market Overview
29.2. Africa Nasopharyngeal Carcinoma Treatment Market, Segmentation by Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Nasopharyngeal Carcinoma Treatment Market, Segmentation by Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Nasopharyngeal Carcinoma Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Nasopharyngeal Carcinoma Treatment Market Competitive Landscape and Company Profiles
30.1. Nasopharyngeal Carcinoma Treatment Market Competitive Landscape
30.2. Nasopharyngeal Carcinoma Treatment Market Company Profiles
30.2.1. Sanofi S.a.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Pfizer Inc.
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Merck & Co. Inc.
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Novartis AG
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Bristol Myers Squibb Company
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Nasopharyngeal Carcinoma Treatment Market Other Major and Innovative Companies
31.1. AstraZeneca plc
31.2. Eli Lilly and Company
31.3. Amgen Inc.
31.4. C.H. Boehringer Sohn AG & Co. KG.
31.5. Regeneron Pharmaceuticals Inc.
31.6. Astellas Pharma Inc.
31.7. Eisai Co., Ltd.
31.8. Incyte Corporation
31.9. Ipsen S.a.
31.10. Dr. Reddys Laboratories Ltd.
31.11. Hikma Pharmaceuticals plc
31.12. Exelixis Inc.
31.13. BeiGene Ltd
31.14. Taiho Pharmaceutical Co., Ltd.
31.15. Simcere Pharmaceutical Group
32. Global Nasopharyngeal Carcinoma Treatment Market Competitive Benchmarking33. Global Nasopharyngeal Carcinoma Treatment Market Competitive Dashboard34. Key Mergers and Acquisitions in the Nasopharyngeal Carcinoma Treatment Market
35. Nasopharyngeal Carcinoma Treatment Market Future Outlook and Potential Analysis
35.1 Nasopharyngeal Carcinoma Treatment Market in 2028 - Countries Offering Most New Opportunities
35.2 Nasopharyngeal Carcinoma Treatment Market in 2028 - Segments Offering Most New Opportunities
35.3 Nasopharyngeal Carcinoma Treatment Market in 2028 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Nasopharyngeal Carcinoma Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nasopharyngeal carcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for nasopharyngeal carcinoma treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:
1) By Types: Non-Keratinizing Undifferentiated Carcinoma; Non-Keratinizing Differentiated Carcinoma; Keratinizing Squamous Cell Carcinoma
2) By Drug: Ellence; Taxotere; Bleomycin; Methotrexate
3) By Therapy: Chemotherapy; Immunotherapy; Radiation Therapy; Other Therapies
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Key Companies Mentioned: Sanofi S.A.; Pfizer Inc.; Merck & Co. Inc.; Novartis AG; Bristol Myers Squibb Company

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Delivery Format: PDF, Word and Excel Data Dashboard

Methodology

Loading
LOADING...